Thymalin vs epithalon:
the two pillars of the Khavinson longevity protocol.
Thymalin and epithalon are the two most studied peptide bioregulators in the longevity literature, developed by the same research team (Khavinson and Morozov) at the same institution (the USSR Institute of Gerontology) and tested together in the longest human clinical trial ever conducted on therapeutic peptides. Thymalin targets the thymus and immune system; epithalon targets the pineal gland and telomere biology. Together, they address the two primary axes of biological aging — immune decline and chromosomal shortening. This guide covers how thymalin and epithalon compare mechanistically, why they are stacked rather than used in isolation, the 6-year trial data, dosing for the combined protocol, and how to decide which peptide to prioritize if using only one.
Thymalin vs epithalon: mechanism, target, and clinical profile.
| Parameter | Thymalin | Epithalon |
|---|---|---|
| Target organ | Thymus gland | Pineal gland |
| Primary mechanism | T-cell differentiation, immune reconstitution | Telomerase activation, melatonin regulation |
| Peptide class | Polypeptide complex (2–8 amino acids) | Tetrapeptide (Ala-Glu-Asp-Gly) |
| Source | Calf thymus extract | Synthetic (sequence from bovine pineal) |
| Aging axis | Immunosenescence / thymic involution | Telomere shortening / circadian disruption |
| Standard dose | 5–10 mg/day for 5–10 days | 5–10 mg/day for 10–20 days |
| Cycle frequency | 2–4× per year | 1–2× per year |
| Key clinical data | Immune restoration, -28% all-cause mortality | Telomere lengthening, melatonin normalization |
| Side effects | Minimal (restlessness rare, with epithalon) | Minimal (sleep changes, vivid dreams) |
| FDA status | Not FDA-approved (approved in Russia) | Not FDA-approved (research compound) |
The comparison between thymalin and epithalon is not really "versus" — the two peptides target entirely different biological systems and are designed to be complementary. Thymalin peptide restores the immune system from the thymus down: T-cell differentiation, NK cell modulation, cytokine balance, and the correction of age-related immunosenescence. Epithalon restores endocrine and chromosomal health from the pineal gland out: telomerase activation (the enzyme that rebuilds telomere caps on chromosomes), melatonin secretion normalization, and circadian rhythm regulation.
Where they converge is at the level of gene expression. Both thymalin and epithalon are peptide bioregulators — short amino acid sequences that interact with DNA to modulate the expression of genes associated with aging. Thymalin regulates gerontogenes involved in immune function, inflammation, and cellular differentiation. Epithalon regulates genes involved in telomere maintenance, oxidative stress response, and neuroendocrine function. The combination addresses aging at two independent genetic regulatory levels simultaneously, which is the theoretical basis for the Khavinson protocol.
Thymalin and epithalon: the Khavinson longevity protocol.
The thymalin-epithalon stack is the most evidence-backed peptide combination in longevity research. The Khavinson & Morozov 6-year trial (2003) tested this combination in 266 elderly patients and produced results that remain unmatched in the peptide literature: a 28% reduction in all-cause mortality and a 45% reduction in cardiovascular mortality in the treated groups compared to untreated controls. No other peptide combination has produced mortality data of this magnitude in a controlled human trial.
The protocol used in the trial administered thymalin and epithalon in annual cycles. Both peptides follow the same short-cycle paradigm: 5–10 mg daily for a defined period, then discontinued until the next cycle. In practice, many longevity-focused practitioners run thymalin and epithalon concurrently — 10 mg of each daily for 10 days, twice per year. Some practitioners separate the two peptides by 1–2 weeks (thymalin first, then epithalon) to reduce the chance of the restlessness and mood instability that a small number of users have reported during concurrent use.
The combined annual burden is modest: 20 days of injections per year (or 40 days if the cycles are separated) for a protocol that produced the strongest human longevity data in the peptide literature. This is one of the lowest-burden longevity interventions available in terms of actual treatment time.
Which to prioritize if choosing one
If budget, supply, or preference limits you to one peptide: choose thymalin if your primary concern is immune function, infection susceptibility, or inflammatory conditions. Choose epithalon if your primary concern is sleep quality, circadian rhythm disruption, or telomere-focused anti-aging. If your goal is general longevity with no specific complaint, the clinical data slightly favors the combination — but thymalin's immune restoration effects may be more immediately perceptible than epithalon's telomere effects, which operate on a longer biological timescale.
Thymalin vs epithalon FAQ.
Can thymalin and epithalon be taken at the same time?
Yes. The Khavinson & Morozov 6-year trial used thymalin and epithalon together, and concurrent administration is the most common protocol in practice. Some users inject both peptides at the same time of day (in separate syringes, separate injection sites). Others separate them by timing (thymalin morning, epithalon evening) or by cycling (thymalin week 1, epithalon week 2). All approaches are used in practice; the clinical trial did not specify injection timing relative to each other. The small number of restlessness reports came from concurrent use, so separation may be preferred for sensitive individuals.
Is thymalin or epithalon more important for anti-aging?
They target different aging mechanisms, so "more important" depends on which axis of aging is more relevant to the individual. Thymalin peptide addresses immunosenescence — the decline in immune function that makes older adults more susceptible to infections, cancers, and chronic inflammation. Epithalon addresses telomere shortening and circadian disruption — the chromosomal and endocrine mechanisms of cellular aging. Both contribute to the overall aging phenotype. The clinical data tested them together and produced mortality reduction from the combination, so separating their individual contributions is difficult.
How long should you run the thymalin-epithalon stack?
The standard protocol runs both peptides at 10 mg daily for 10 days, constituting one cycle. This cycle is repeated 1–2 times per year for ongoing longevity benefit. The 6-year trial administered annual cycles, suggesting that long-term repeated use is both the intended protocol and the one with clinical backing. There is no published evidence for diminishing returns over repeated annual cycles — in fact, the mortality data suggests cumulative benefit over the 6-year observation period.
What is the difference between epithalon and epitalon?
Epithalon and epitalon are the same compound — the tetrapeptide Ala-Glu-Asp-Gly. The spelling variation reflects transliteration from the Russian "Эпиталон." Both spellings appear in the English-language literature, with "epithalon" being more common in recent publications and "epitalon" appearing in older or directly translated sources. The peptide is also known as epithalone and epithalamine in some references. All refer to the same synthetic tetrapeptide derived from the bovine pineal gland peptide epithalamin.